Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 499 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Hansa Biopharma rapporterar positiva effekt- och säkerhetsresultat från den bekräftande europeiska studien av Idefirix vid njurtransplantation
Regulatory Filings Classification · 82% confidence The document is a corporate press release announcing clinical trial results (positive efficacy and safety data for Idefirix) and associated regulatory next steps, plus a conference call schedule. It does not contain financial statements or performance metrics (so not an earnings release or interim/annual report), nor is it a presentation transcript, board change, or capital/financing notice. It is a mandatory disclosure under EU Market Abuse Regulation, making it a regulatory announcement. The best fit is Regulatory Filings (RNS).
2026-05-27 Swedish
Hansa Biopharma reports positive efficacy and safety results from Idefirix[®] European post authorization study in kidney transplantation
Regulatory Filings Classification · 75% confidence The document is a company press release reporting clinical trial topline results and announcing a conference call pursuant to EU Market Abuse Regulation. It does not contain financial statements, proxy materials, or earnings data, nor is it an actual financial report (e.g., 10-K, interim report) or a presentation in slide deck form. It is a regulatory announcement of material news about the drug’s post‐authorization study. This best fits the fallback category for general regulatory disclosures (RNS).
2026-05-27 English
Hansa Biopharma ingår licensavtal värt 115 miljoner euro med SERB Pharmaceuticals för IDEFIRIX i Europa och MENA
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a licensing agreement between Hansa Biopharma and SERB Pharmaceuticals for the commercialization of a drug (IDEFIRIX) in Europe and MENA regions. It includes details about the financial terms of the deal, strategic implications, and background information about the drug and companies involved. It also mentions a conference call for investors. The document does not contain financial statements, detailed financial performance data, or comprehensive management discussion and analysis. It is primarily an announcement of a capital/financing transaction and strategic partnership. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the financing and licensing deal, supporting a high confidence classification.
2026-05-19 English
Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a €115 million licensing agreement between Hansa Biopharma and SERB Pharmaceuticals for the commercialization of IDEFIRIX in Europe and MENA. It includes details about the agreement, financial terms, strategic implications, and a conference call announcement. The document does not contain financial statements, detailed financial performance data, or comprehensive management discussion and analysis. It is primarily a corporate announcement about a licensing deal and related financial terms, not a report or transcript. The presence of a conference call announcement suggests it is related to investor communication but is not itself a call transcript or investor presentation. Given these characteristics, the document best fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length (over 12,000 characters) and detailed content support this classification rather than a brief announcement or regulatory filing.
2026-05-19 English
Notice to Annual General Meeting in Hansa Biopharma AB (publ)
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a detailed notice to shareholders of the upcoming Annual General Meeting, including participation instructions, agenda items, proposals, proxy and advance voting procedures. This is exactly proxy solicitation / information statement material sent to shareholders ahead of an AGM. Therefore it should be classified as PSI.
2026-04-28 English
Kallelse till årsstämma i Hansa Biopharma AB (publ)
Proxy Solicitation & Information Statement Classification · 87% confidence The document is a formal notice (“kallelse”) convening an Annual General Meeting, including agenda items, participation instructions, voting procedures, and detailed proposals to shareholders. It is sent to shareholders to provide information and solicit votes, matching the definition of a Proxy Solicitation & Information Statement.
2026-04-28 Swedish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.